Medtronic, a leading medical technology company, has reached a significant milestone in the journey to bring its Infuse bone graft for transforaminal lumbar interbody fusion (TLIF) procedures to the U.S. market. Following a successful interim analysis, an independent Data Monitoring Committee recommended halting further enrollment in the FDA investigational device exemption (IDE) study. This positive development has set the stage for Medtronic to prepare a premarket approval (PMA) submission to the FDA. The study, focused on evaluating the safety and effectiveness of Infuse in TLIF procedures for patients with degenerative lumbar spine conditions, underwent a protocol amendment in April to enhance its design. With the incorporation of both PEEK and titanium cages, the study aims to broaden the clinical applicability of Infuse. If approved, a new indication for Infuse could offer expanded treatment options for spine surgery patients, marking a significant advancement in the field of biotechnology. Medtronic’s commitment to regulatory compliance and patient safety is evident in their dedication to delivering a high-quality PMA submission that aligns with the highest standards set by the FDA.
Read more from massdevice.com